BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ...

BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

BofA analyst Tim Anderson slightly reduced the price forecast from $160 to $159 with a Neutral rating. Stifel noted Johnson & Johnson started the fourth-quarter 2024 MedTech earnings season on a ...

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...

Waxing bullish about the effects of Novo Nordisk's latest findings on Eli Lilly sentiment was Bank of America Securities analyst Tim Anderson. On the back of those clinical trial results ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Terence Flynn, Morgan Stanley, inquired about Zepbound payer dynamics and access. Patrik Jonsson explained that Medicare coverage related to obstructive sleep apnea (OSA) is anticipated in the second ...

BofA Securities reiterated a 'Buy' rating with a $997 price target, according to Investing.com. Analyst Tim Anderson emphasized that despite short-term challenges, Lilly remains a dominant player ...

Following a second day of stock market gains, investors looked forward to earnings reports from Eli Lilly and Amazon.